ZA200709851B - Inhibitors of VEGF receptor and HGF receptor signaling - Google Patents

Inhibitors of VEGF receptor and HGF receptor signaling

Info

Publication number
ZA200709851B
ZA200709851B ZA200709851A ZA200709851A ZA200709851B ZA 200709851 B ZA200709851 B ZA 200709851B ZA 200709851 A ZA200709851 A ZA 200709851A ZA 200709851 A ZA200709851 A ZA 200709851A ZA 200709851 B ZA200709851 B ZA 200709851B
Authority
ZA
South Africa
Prior art keywords
receptor
inhibitors
hgf
signaling
vegf
Prior art date
Application number
ZA200709851A
Other languages
English (en)
Inventor
Saavedra Oscar Mario
Zhan Lijie
Vaisburg Arkadii
Deziel Robert
Nancy Z Zhou
Claridge Stephen William
Raeppel Franck
Raeppel Stephane
Mannion Michael
Isakovic Ljubomir
Original Assignee
Methylgene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methylgene Inc filed Critical Methylgene Inc
Publication of ZA200709851B publication Critical patent/ZA200709851B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA200709851A 2005-05-20 2007-11-15 Inhibitors of VEGF receptor and HGF receptor signaling ZA200709851B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68303805P 2005-05-20 2005-05-20

Publications (1)

Publication Number Publication Date
ZA200709851B true ZA200709851B (en) 2009-08-26

Family

ID=38023642

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200709851A ZA200709851B (en) 2005-05-20 2007-11-15 Inhibitors of VEGF receptor and HGF receptor signaling

Country Status (15)

Country Link
US (2) US7790729B2 (pt)
EP (1) EP1904504B1 (pt)
JP (1) JP5275792B2 (pt)
KR (1) KR101078968B1 (pt)
CN (1) CN101248080B (pt)
AU (1) AU2006313456B2 (pt)
BR (1) BRPI0610382A2 (pt)
CA (1) CA2608726C (pt)
DK (1) DK1904504T3 (pt)
ES (1) ES2473341T3 (pt)
IL (1) IL187422A0 (pt)
MX (1) MX2007014617A (pt)
NZ (1) NZ563774A (pt)
WO (1) WO2007054831A2 (pt)
ZA (1) ZA200709851B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7202363B2 (en) 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
GEP20105024B (en) 2004-06-02 2010-06-25 Takeda Pharmaceuticals Co Fused heterocyclic compound
RU2007107167A (ru) * 2004-07-30 2008-09-10 Метилджин, Инк. (Ca) Ингибиторы передачи сигнала рецептора vegf и рецептора hgf
AU2006229343A1 (en) * 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
CA2636242A1 (en) * 2006-01-30 2008-05-29 Array Biopharma, Inc. Heterobicyclic thiophene compounds and methods of use
CA2655128A1 (en) * 2006-06-08 2007-12-21 Array Biopharma Inc. Quinoline compounds and methods of use
EP2057140B1 (en) 2006-08-24 2012-08-08 AstraZeneca AB Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
US8138183B2 (en) 2007-07-09 2012-03-20 Astrazeneca Ab Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/or PI3K
KR101556269B1 (ko) * 2007-08-29 2015-09-30 메틸진 인코포레이티드 단백질 티로신 키나아제 활성의 억제제
WO2009026720A1 (en) 2007-08-29 2009-03-05 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
SG182146A1 (en) * 2008-03-05 2012-07-30 Methylgene Inc Inhibitors of protein tyrosine kinase activity
BRPI0920765A2 (pt) * 2008-10-29 2015-08-18 Deciphera Pharmaceuticals Llc Amidas de cilopropano e análogos que exibem atividades anticâncer e antiproliferativas
PE20110830A1 (es) 2008-12-05 2011-12-14 Abbvie Bahamas Ltd Derivados de tieno[3,2-c]piridina como inhibidores de quinasas
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
MX2012002591A (es) * 2009-09-03 2012-04-02 Allergan Inc Compuestos como moduladores de tirosina cinasas.
MX2012012031A (es) * 2010-04-16 2012-12-17 Methylgene Inc Inhibidores de la actividad de la proteina tirosina quinasa y uso de los mismos para tratar transtornos oftalmicos.
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
US8664244B2 (en) 2010-09-12 2014-03-04 Advenchen Pharmaceuticals, LLC Compounds as c-Met kinase inhibitors
WO2012035039A1 (en) 2010-09-15 2012-03-22 F. Hoffmann-La Roche Ag Azabenzothiazole compounds, compositions and methods of use
CN102153579B (zh) * 2011-02-23 2013-05-29 兰州米诺生物科技有限公司 氮-叔丁氧羰基-1,2,5,6-四氢吡啶-4-硼酸频哪醇酯的合成方法
CN102827186A (zh) * 2011-06-16 2012-12-19 中国科学院上海药物研究所 一类吡啶并五元杂环衍生物及其制备方法和用途
BR112014000314A2 (pt) 2011-07-08 2017-01-10 Novartis Ag derivados de pirrolo pirimidina
WO2013012909A1 (en) 2011-07-20 2013-01-24 Abbott Laboratories Kinase inhibitor with improved aqueous solubility
CN104220058A (zh) 2012-01-27 2014-12-17 国立大学法人富山大学 丝氨酸消旋酶抑制剂
GB2499666A (en) * 2012-02-27 2013-08-28 Nanyang Polytechnic Mcl-1 inhibitors for the treatment of conditions associated with proliferative disorders
CN104507930B (zh) * 2012-06-29 2017-10-10 贝达药业股份有限公司 作为c‑Met酪氨酸激酶抑制剂的新型稠合吡啶衍生物
TWI520962B (zh) * 2012-06-29 2016-02-11 As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives
JP6218848B2 (ja) * 2012-11-20 2017-10-25 プロキナーゼ ゲゼルシャフト ミット ベシュレンクテル ハフツング プロテインキナーゼ阻害剤としてのチオエーテル誘導体
CN103396417B (zh) * 2013-08-14 2015-02-04 冯子侠 新型羟肟酸衍生物及其医疗应用
CN106995452B (zh) * 2016-12-22 2018-03-16 湖北民族学院 一种噻吩并[3，2‑d]嘧啶类EGFR/ErbB2双靶点抑制剂及其制备方法和用途
AR117472A1 (es) 2018-12-21 2021-08-11 Celgene Corp Inhibidores de tienopiridina de ripk2
US10702525B1 (en) 2019-09-04 2020-07-07 United Arab Emirates University Pyrimidine derivatives as anti-diabetic agents

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107300A (en) * 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
WO1999024440A1 (en) 1997-11-11 1999-05-20 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
CA2333770A1 (en) 1998-06-04 1999-12-09 Abbott Laboratories Cell adhesion-inhibiting antinflammatory compounds
US6232320B1 (en) * 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
WO2000075145A1 (en) 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
JP2003535867A (ja) 2000-06-06 2003-12-02 ファイザー プロダクツ インコーポレイテッド 抗癌剤として有用なチオフェン誘導体
US20020004511A1 (en) * 2000-06-28 2002-01-10 Luzzio Michael Joseph Thiophene derivatives useful as anticancer agents
US6488261B1 (en) * 2001-02-21 2002-12-03 Jen-Chieh Lee Ball valve
US6995171B2 (en) * 2001-06-21 2006-02-07 Agouron Pharmaceuticals, Inc. Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
JP4342935B2 (ja) * 2001-06-22 2009-10-14 協和発酵キリン株式会社 肝細胞増殖因子受容体自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物
CA2478050A1 (en) 2002-03-01 2003-09-12 Pfizer Inc. Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents
US20030199525A1 (en) 2002-03-21 2003-10-23 Hirst Gavin C. Kinase inhibitors
CL2003002287A1 (es) * 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
MXPA06002296A (es) 2003-08-29 2006-05-22 Pfizer Tienopiridina-fenilacetamidas y sus derivados utiles como nuevos agentes antiangiogenicos.
US7581674B2 (en) * 2003-11-21 2009-09-01 Charles Cohen Financial transaction system and method
CA2553433A1 (en) * 2004-01-23 2005-08-11 Amgen Inc. Quinoline quinazoline pyridine and pyrimidine compounds and their use in the treatment of inflammation angiogenesis and cancer
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) * 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
WO2005121125A1 (en) * 2004-06-09 2005-12-22 Pfizer Inc. Ether-linked heteroaryl compounds
US7173031B2 (en) * 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
WO2006014325A2 (en) * 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
JP2008506714A (ja) 2004-07-16 2008-03-06 サネシス ファーマシューティカルズ， インコーポレイテッド オーロラキナーゼインヒビターとして有用なチエノピリミジン
RU2007107167A (ru) * 2004-07-30 2008-09-10 Метилджин, Инк. (Ca) Ингибиторы передачи сигнала рецептора vegf и рецептора hgf
AU2006229343A1 (en) * 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
ES2623221T3 (es) 2005-05-20 2017-07-10 Methylgene Inc Inhibidores de la señalización del receptor de VEGF y del receptor de HGF
CA2636242A1 (en) 2006-01-30 2008-05-29 Array Biopharma, Inc. Heterobicyclic thiophene compounds and methods of use

Also Published As

Publication number Publication date
US7790729B2 (en) 2010-09-07
BRPI0610382A2 (pt) 2010-06-15
KR101078968B1 (ko) 2011-11-01
EP1904504A4 (en) 2010-06-02
DK1904504T3 (da) 2014-06-23
AU2006313456A1 (en) 2007-05-18
JP5275792B2 (ja) 2013-08-28
WO2007054831A3 (en) 2007-10-04
CN101248080A (zh) 2008-08-20
MX2007014617A (es) 2008-02-11
EP1904504A2 (en) 2008-04-02
CA2608726A1 (en) 2007-05-18
WO2007054831A2 (en) 2007-05-18
ES2473341T3 (es) 2014-07-04
KR20080027782A (ko) 2008-03-28
JP2008540639A (ja) 2008-11-20
EP1904504B1 (en) 2014-03-19
AU2006313456B2 (en) 2011-06-23
US20100249145A1 (en) 2010-09-30
CN101248080B (zh) 2012-09-05
NZ563774A (en) 2010-04-30
US20060287343A1 (en) 2006-12-21
IL187422A0 (en) 2008-02-09
CA2608726C (en) 2013-07-09

Similar Documents

Publication Publication Date Title
IL187484A0 (en) Inhibitors of vegf receptor and hgf receptor signaling
IL187422A0 (en) Inhibitors of vegf receptor and hgf receptor signaling
IL180788A0 (en) Inhibitors of vegf receptor and hgf receptor signaling
HK1203527A1 (en) Vegf analogs and methods of use vegf
EP2083861A4 (en) ANTAGONISTS OF PCSK9
EP2083859A4 (en) ANTAGONISTS OF PCSK9
EP2083860A4 (en) PCSK9 ANTAGONISTS
EP2106261A4 (en) ANTAGONISTS OF PCSK9
IL227215A (en) Vegf antagonists
CY2013042I1 (el) Αναστολεις πυριδυλιου της σηματοδοτησης hedgehog
EP1976529A4 (en) COMBINATIONS OF ANG2 AND VEGF INHIBITORS
GB0611154D0 (en) Novel receptor antagonists and their methods of use
ZA200804082B (en) Compositions and methods for controlling tissue factor signaling specificity
IL197749A0 (en) Cytokine signaling
EP1806147A4 (en) USE OF IMMUNOSUPPRESSIVE RECEPTOR
EP1778878A4 (en) METHOD AND COMPOSITIONS FOR DETECTING RHINOVIRES
EP1739047A4 (en) DAMPING DEVICE FOR ONE ELEVATOR
HK1103651A1 (en) Vegf inhibition vegf
ZA200804681B (en) Inhibitors of C-Met and uses thereof
ZA200710843B (en) Inhibitors of VEGF receptor and HGF receptor signaling
GB0601098D0 (en) Vegf variants
ITMO20040070A1 (it) Apparato segnalatore
GB2422232B (en) Course and sail-plan predictor
DE112007002472A5 (de) Chockerseil und Chockerseilsystem
IL187936A0 (en) Joining device of passage block